ArticleCancer medicine2022
Prognostic impact of tumor size on patients with neuroblastoma in a SEER-based study.
Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Machine learning-based analysis of cancer cell-derived vesicular proteins revealed significant tumor-specificity and predictive potential of extracellular vesicles for cell invasion and proliferation - A meta-analysis.Cell communication and signaling : CCS · 2023Pooled it
- A practical nomogram and risk stratification system for predicting survival outcomes in neuroblastoma patients: a SEER population-based study.Journal of cancer research and clinical oncology · 2023Trial
- Adult-onset neuroblastic tumor: An extremely rare entity in the adult population.Radiology case reports · 2026Article
- Development and internal validation of an XGBoost-based prognostic prediction model and risk stratification system for overall survival in pediatric neuroblastoma: a SEER-based study.Translational pediatrics · 2026Article
- Tumor size predicts metastatic disease at diagnosis and prognosis in unilateral Wilms tumor: a population based study with external validation.Discover oncology · 2026Article
- Bilateral blindness from optic chiasm metastasis as the initial presentation of stage 4 neuroblastoma: A case report.Medicine · 2026Article
- Identification of potential clinical markers associated with prognosis of neuroblastoma.Discover oncology · 2026Article
- The baselineBMC medical imaging · 2025Article
- Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research.Molecular neurobiology · 2025Review
- Evaluation of optimal strategies for breast cancer screening in Ghana: A simulation study based on a continuous tumor growth model.PloS one · 2025Article
- Prognostic impact of tumor size on cancer-specific survival for postoperative WHO grade II oligodendroglioma: a SEER-based study.Frontiers in surgery · 2025Article
- Multicellular model of neuroblastoma proposes unconventional therapy based on multiple roles of p53.PLoS computational biology · 2024Article
- Dual roles of HK3 in regulating the network between tumor cells and tumor-associated macrophages in neuroblastoma.Cancer immunology, immunotherapy : CII · 2024Article
- A clinical prediction model for distant metastases of pediatric neuroblastoma: an analysis based on the SEER database.Frontiers in pediatrics · 2024Article
- Construction of a novel clinical nomogram to predict cancer-specific survival in patients with primary malignant adrenal tumors: a large population-based retrospective study.Frontiers in medicine · 2023Article
- Establishment and validation of a nomogram to predict cancer-specific survival in pediatric neuroblastoma patients.Frontiers in pediatrics · 2023Article
- Association of Image-Defined Risk Factors with Clinical, Biological Features and Outcome in Neuroblastoma.Children (Basel, Switzerland) · 2022Article
- Prognostic impact of tumor size on patients with neuroblastoma in a SEER-based study.Cancer medicine · 2022Article
- Surgical Treatment of Adrenal Neuroblastoma in Children - A Narrative Review.International braz j urol : official journal of the Brazilian Society of UrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe prognostic value of tumor size in neuroblastoma (NB) patients has not been fully evaluated. Our purpose is to elucidate the prognostic significance of tumor size in surgery performed on neuroblastoma patients.
methodsNeuroblastoma patients diagnosed from 2004 to 2015 were selected from the Surveillance, Epidemiology, and End Results Program (SEER) for the study. Univariate and multivariate Cox proportional hazard regression models were used to identify risk factors and the independent prognostic influences of tumor size on NB patients. Overall survival (OS) was analyzed through univariate Cox regression analysis. To determine the optimal cutoff value of tumor size, we first divided the cohort into three groups (≤5 cm, 5-10 cm, >10 cm). Subsequently, the patients were divided into two groups repeatedly, with tumor size at 1 cm intervals. The cutoff value that maximized prognostic outcome difference was selected. Furthermore, we performed the Kaplan-Meier methods to visually present differences in prognosis between the optimal tumor size cutoff value in different subgroups.
resultsA total of 591 NB patients who met the inclusion criteria were selected from the SEER database in this study. Cox analysis showed that age >1 year (HR = 2.42, p < 0.0001), originate from adrenal site (HR = 1.7, p = 0.014), distant stage (HR = 6.4, p < 0.0001), undifferentiated grade (HR = 1.94, p = 0.002), and large tumor size (HR = 1.5, p < 0.0001) independently predicted poor prognosis. For tumor size, there were significant differences in tumor size distribution in different ages, tumor grade, disease stage, and primary site subgroup but not in sex, race, and histology subgroup. Furthermore, both univariate (HR = 4.96, 95% CI 2.31-10.63, p < 0.0001) and multivariable analysis (HR = 2.8, 95% CI 1.29-6.08, p < 0.0001) indicated the optimal cutoff value of tumor size was 4 cm for overall survival of NB patients. Using a 4 cm of tumor size cutoff in subgroups, we found that it can identify poor prognosis patients whatever their age or primary site. Interestingly, tumor size of 4 cm cutoff can only identify unfavorable NB patients with diagnosis at distant-stage disease, or differentiated grade tumor, but not with regional and local or undifferentiated tumor.
conclusionsTumor size is first to be recognized as a key prognostic factor of neuroblastoma patients and a cutoff value >4 cm might predict poor prognosis, which should be included in the evaluation of prognostic factors for NB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.